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Summary: We report a potentiometric fully automated method for determining red cell glucose 6-phosphate dehy-
drogenase, 6-phosphogluconate dehydrogenase activities and the glucose 6-phosphate dehydrogenase/6-phosphoglu-
conate dehydrogenase index using 25 μΐ of whole blood. No sample pre-treatment (e. g., preparation of the haemoly-
sate) is needed and the measurements are performed at pH 8.0 and 37 °C under the conditions recommended by
the ICSH committee. The reproducibility was constantly good, with within-run CV of 1.0% (glucose 6-phosphate
dehydrogenase) and 5.9% (glucose 6-phosphate dehydrogenase/6-phosphogluconate dehydrogenase) for activities
in glucose 6-phosphate dehydrogenase non-deficient adults, and of 2.3% (glucose 6-phosphate dehydrogenase,
G6PD) and 2.5% (glucose 6-phosphate dehydrogenase/6-phosphogluconate dehydrogenase) for G6PDMediterranean
heterozygotes. Linearity was observed up to an activity of 2800 U/l of glucose 6-phosphate dehydrogenase. Results
of glucose 6-phosphate dehydrogenase activity (U/l) in whole blood (y) correlated well with those obtained with
the previously described monostarter assay, performed at pH 9.2 (y = 0.60x + 37; η = 80; r = 0.991). Results of
6-phosphogluconate dehydrogenase (U/l) in whole blood (y) correlated well with those obtained by the ICSH
recommended method (x) (y = 0.779x - 44; n = 23; r = 0.991). Reference intervals are reported for glucose 6-
phosphate dehydrogenase, 6-phosphogluconate dehydrogenase and glucose 6-phosphate dehydrogenase/6-phospho-
gluconate dehydrogenase index relatively to normal, β- and α-thalassaemic glucose 6-phosphate dehydrogenase
non-deficient adults, to glucose 6-phosphate dehydrogenase deficient adult males and to G6PDMediterrancan non-
thalassaemic heterozygotes. We demonstrate that the diagnostic sensitivity of the glucose 6-phosphate dehydroge-
nase/6-phosphogluconate dehydrogenase index in detecting the G6PDMediterrancan heterozygotes is superior to that
of the glucose 6-phosphate dehydrogenase activity alone.
Introduction
The quantitative determination of glucose 6-phosphate ficient erythrocytes (2). Finally, the determination of
dehydrogenase2) activity is clinically important in cases glucose 6-phosphate dehydrogenase activity is indicated
of chronic non-spherocytic haemolytic anaemia, or in for the detection of heterozygote females. As a curiosity,
episodic haemolytic anaemia caused by drugs or infec- severe deficiency of glucose 6-phosphate dehydrogenase
tions (1). The test must also be performed in cases of has recently been reported in horses, so that the determi-
severe neonatal jaundice and before the administration nation of glucose 6-phosphate dehydrogenase activity
of oxidant haemolytic drugs, while its use in transfu- could also be of interest in veterinary medicine (3).
sional medicine is controversial, although posttransfti- fa European countries, glucose 6-phosphate dehydroge-
sional haemolytic reactions were seldom demonstrated nase deficiency is frequently associated with the glucose
in recipients of glucose 6-phosphate dehydrogenase-de- 6_phosphate dehydrogenaseMcdilc—, a variant with
very low activity. The highest frequency is found in
Greece (overall frequency of male glucose 6-phosphate
1) Funding organisation: dehydrogenase deficiency: 18%), followed by Sardinia
Work partially supported by Target Project BTBS, CNR and by /14-0/λ * .. T. , /00// A c · / I O / N />· *\ u-M U R S T 60% (15%), North Italy (2%) and Spam (1%) (4-6). How-
2) Enzymes ever, because of recent immigrations from high inci-
Glucose 6-phosphate dehydrogenase (D-Glucose 6-phosphate : ^ence areas cases of glucose 6-phosphate dehydroge-
NADP oxidoreductase, EC 1.1.1.49); , ~ . i u *· j - *u · · j «. · ι
Phosphogluconate dehydrogenase (6-phospho-D-gluconate : nase deficiency can also be found m the major industrial
NADP oxidoreductase, decarboxylating, EC 1.1.1.44). cities of Central and Northern Europe.
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Several spectrophotometric methods are available for ac-
curately determining glucose 6-phosphate dehydroge-
nase activity, which has to be measured free of interfer-
ence from 6-phosphogluconate dehydrogenase2) activity.
This can be accomplished by inhibiting the 6-phospho-
gluconate dehydrogenase activity with maleimide (7) or
by subtraction of the 6-phosphogluconate dehydroge-
nase activity, performed in a separate set of measure-
ments, as recommended by the WHO protocol (8). Some
years ago, as an alternative to the spectrophotometric
assay, a new rapid potentiometric method for the quanti-
tative determination of glucose 6-phosphate dehydroge-
nase in whole blood and isolated red cells was presented
(9). Such an assay was successfully applied to the glu-
cose 6-phosphate dehydrogenase deficiency detection in
areas with high prevalence of the disease (10). The
method was based on differential pH measurements per-
formed directly on 10 μΐ whole blood and was later fol-
lowed by protocols for the determination of other red
cell enzymes activities (11, 12).
A problem common to the different techniques for glu-
cose 6-phosphate dehydrogenase activity determination
and, more generally, to the determination of the activity
of any red cell enzyme, concerns the expression of the
enzymatic activity. This can be reported in terms of
U/g Hb, the most frequently used units, or in terms of
units per fixed number of erythrocytes (U/1012 erythro-
cytes). However, in cases of anaemias not associated
with glucose 6-phosphate dehydrogenase deficiency,
such as iron deficiency or -thalassaemia trait (10),
higher than normal glucose 6-phosphate dehydrogenase
activities are found with both units. As a consequence,
separate reference intervals for the various syndromes
are needed.
In this report we present a new protocol for the simulta-
neous determination of the glucose 6-phosphate dehy-
drogenase/6-phosphogluconate dehydrogenase index in
whole blood, by using an improved version of the dif-
ferential pH system already applied to the determination
of glucose 6-phosphate dehydrogenase activity (9). We
also report on the utility of the glucose 6-phosphate de-
hydrogenase/6-phosphogluconate dehydrogenase index
in a geographic area with a high prevalence of glucose
6-phosphate dehydrogenase deficiency and thalassaemic
syndromes. Finally, by using a rapid method suitable for
identifying the glucose 6-phosphate dehydrogenaseMedi-
terranean variant at the DNA levdj we evaluate tfae geno.
type-phenotype relationship in a subgroup of heterozy-
gotes for the G6PDMediterranean variant.
Materials and Methods
Specimens
Blood samples collected in sodium EDTA for routine laboratory
complete blood counts were analysed shortly after withdrawal.
Erythrocytes freed from leukocytes and platelets were prepared by
blood filtration through α-cellulose and microcrystalline cellulose
(13).
All the cell count values of normocytic samples (from subjects
between 16-17 years of age) were within normal ranges. The diag-
nosis of -thalassaemia trait was based on increased Hb A2 levels
(> 3.5%) associated with microcytosis, reduced MCH3) and nor-
mal serum iron. α-Thalassaemia trait was suspected in subjects
showing reduced MCV3) and MCH, normal serum iron, Hb A2 and
Hb F. The diagnosis of α-thalassaemia trait was confirmed by glo-
bin synthesis (α/β ratio < 0.9) or α globin 'gfene DNA analysis.
Glycerol-stabilised haemolysates for use as control material were
prepared as described (14). The low glucose o^phosphate dehydro-
genase activity lot was prepared by warming an aliquot of the nor-
mal activity batch at 50 °C for 50 min.
Instrumentat ion
The analyses were performed at 37 °C on a differential pH analyser
(CL50, Eurochem sri, 00040 Ardea, Rome, Italy) equipped with
cell top and software for double starter procedures. Total blood
cell count and haemoglobin concentration were determined with a
Coulter S Plus electronic counter (Kontron AG). Hb A2 was quanti-
fied with the HPLC Variant (Βίο-Rad Laboratories, Milano, Italy).
Principle of the assays
The glucose 6-phosphate dehydrogenase and 6-phosphogluconate
dehydrogenase activities were measured by following the pH
changes produced in the reaction buffer during the conversions of
NADP+ to NADPH and H+.
Working solutions
A stock buffer with the following composition was prepared: TRJS
(10 mmol/1), KC1 (100 mmol/1), MgCl2 (10 mmol/1), EDTA (0.5
mmol/1), NaN3 (1 g/1) and Triton X-100 (1 g/1). Its pH was lowered
to 8.6 with concentrated HC1. The solution was stable one month
at room temperature. The working buffer was prepared by adding
NADP 0.6 mmol/1, final concentration. The pH of the working
buffer was 8.00 ± 0.05 at 25 °C. It was prepared fresh every week.
Glucose 6-phosphate (65 mmol/1) in NaN3 (1 g/1) and 6-phospho-
gluconate (25 mmol/1), both at pH 8.0 were prepared fresh every
week and stored at + 4 °C.
Differential pH procedures
The assays were performed on 25 μΐ of whole blood, with 6-phos-
phogluconate added as starter 1 and glucose 6-phosphate as
starter 2.
The sample was added manually to the mixing chamber filled with
1170 μΐ of the working buffer. After dilution and lysis of the red
cell membranes (10 s), part of the reaction mixture was automati-
cally injected into each of the capillary electrodes, and 15 μΐ of the
first starter were added to the mixing chamber, which contained
800 μΐ of the reaction mixture. After further mixing, this reaction
mixture plus substrate was injected into only one electrode. The
variation of pH between the two electrodes after a lag phase of 30 s
was recorded for 30 s and used to calculate the 6-phosphogluconate
dehydrogenase enzymatic activity. For the measurement of the se-
cond enzymatic activity 15 μΐ of the second starter were added to
the mixing chamber, which contained 300 μΐ of the reaction mix-
ture. After further mixing, this reaction mixture plus substrate was
injected into the other electrode. The variation of pH between the
two electrodes after a lag phase of 30 s was recorded for 30 s and
used to calculate the glucose 6-phosphate dehydrogenase enzy-
matic activity.
3) MCH = Mean corpuscular haemoglobin
MGV = Mean corpuscular volume
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CV Mean SD CV
Within-run (n = 20)
Normal subjects 1040 10 1.0 768 44 5.8' 1.36 0.08 5.9
G6PDB/G6PDMcda subjects 329 8 2.3 835 21 2,5 0.40 0.01 2.5
G6PDMedb subjects 51 Π 21.7 946 13 1.4 0.06 0.01 21.7





















0 Glucose 6-phosphate dehydrogenase heterozygous female
b Glucose 6-phosphate dehydrogenase deficient male
c Glycerol-stabilised haemolysate
d Glycerol-stabilised haemolysate, heat-treated (50 °C, 50 min)
An autosampler with capacity for 50 samples was loaded automati-
cally with the specimen (300 μΐ whole blood per vial). The au-
tosampler probe tip aspirated from the bottom of each sample vial
and injected 25 μΐ of sample into the mixing chamber of the dif-
ferential pH apparatus.
Calculations of the enzymatic activities were automatically per-
formed by the instrument, as described for other enzymatic assays
(9, 12). The following main instrumental variables were set:
slope 1: -186; slope 2: 93.
The glucose 6-phosphate dehydrogenase activity was also mea-
sured under optimised conditions with the differential pH tech-
nique, using the previously described monostarter kit (10).
DNA analysis
Genomic DNA was isolated from leukocytes and purified by the
method of Goossens & Kan (15). The polymerase chain reaction
(PCR) was carried out according to Saiki et al. (16). The Mediterra-
nean glucose 6-phosphate dehydrogenase mutation was detected
according to Kurdi-Haidar et al. (17). The G6PDMediterrancan muta-
tion at position 563 (C —* T), creates a novel Mho II site in exon
VI of the glucose 6-phosphate dehydrogenase gene. To identify
subjects earring this mutation a fragment containing exons VI and
VII was amplified using the following primers:
(a) 5' ACTCCCGAAGAGGGGTTCCAAGG 3',
(b) 3' GAAGGAGAGAGGACCCTCCGACC 5'.
The DNA amplified fragment was digested with Mbo II restriction
enzyme and the digestion fragments were analysed on agarose gel.
Statistical analysis
The results were analysed by a commercial statistical program
(LABSTAT vs 3.03, Bio-Rad Laboratories, Milano). Kurtosis,
asymmetry and Kolmogorov-Sminwv's tests were used to deter-
mine whether distributions were Gaussian. Means of duplicate as-
says were used for evaluating between-run reproducibility. Groups
were compared by the Wilcoxon test for unpaired observations. The
Pearson correlation coefficient was calculated to compare the asso-
ciation between variables. Linear regression analysis was per-
formed with the least-squares method. Values of P < 0.05 were
considered statistically significant.
Results
Under our experimental conditions the lag and measur-
ing times were found adequate to obtain steady state
kinetics. In terms of pH change per minute, a normal
sample gave approximatively 0.006 pH/min and 0.013
pH/min with the 6-phosphogluconate dehydrogenase
and glucose 6-phosphate dehydrogenase reactions,
respectively.
The within-run reproducibility (tab. 1) was assessed by
measuring twenty times three samples with normal and
reduced glucose 6-phosphate dehydrogenase activities.
The glucose 6-phosphate dehydrogenase activity had the
best score in terms of CV, but both glucose 6-phosphate
dehydrogenase and 6-phosphogluconate dehydrogenase
activities were measured with similar SD, in terms of
U/l.
The between-run reproducibility was evaluated by meas-
uring, during four months, two glycerol-stabilised
haemolysates; it was found to be similar to the within-
run reproducibility. The coefficient of variations calcu-
lated, in the same period, on blood specimens measured
in duplicate, were 3.9%, 4.9% and 5.3% for the glucose
6-phosphate dehydrogenase activity, 6-phosphogluco-
nate dehydrogenase activity and glucose 6-phosphate de-
hydrogenase/6-phosphogluconate dehydrogenase index,
respectively.
The linearity test was performed by assaying 11 serial
dilutions of washed erythrocytes isolated from a non-
deficient adult male (glucose 6-phosphate dehydroge-
nase 1361 U/l; glucose 6-phosphate dehydrogenase/6-
phosphogluconate dehydrogenase index 1.69) with the
red cells obtained from a glucose 6-phosphate dehydro-
genase deficient male (glucose 6-phosphate dehydroge-
nase 35 U/l; glucose 6-phosphate dehydrogenase/6-
phosphogluconate dehydrogenase index 0.04). Each ali-
quot was measured in triplicate. The linear-regression
analysis of the glucose 6-phosphate dehydrogenase ac-
tivity (y, U/l) vs. the percentage of the "high activity
sample" (x) calculated on the 5 dilutions at lower activ-
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ity concentration was as follows: y = 12.9x + 35.6;
r = 0.9996. Moreover, the linear-regression analysis of
the glucose 6-phosphate dehydrogenase/6-phosphoglu-
conate dehydrogenase index (y!) vs. the percentage of
the "high activity sample" (xf) calculated on the same 5
dilutions at lower activity concentration was:
y1 = 0.017x! + 0.032; r = 0.9981. Using these regres-
sion equations we calculated the theoretical values for
the other 6 dilutions, and the biases between the theoret-
ical and the found. The mean bias relative to the glucose
6-phosphate dehydrogenase linearity test was —0.8%,
and that relative to the glucose 6-phosphate dehydroge-
nase/6-phosphogluconate dehydrogenase index linearity
test was 4.8%. Therefore, both methods were considered
linear. The correlation between the 6-phosphogluconate
dehydrogenase activity and the percentage of the "high
activity sample" was not significant (r = 0.192).
Linearity was also assessed on blood samples, using vol-
umes between 5 and 80 μΐ. The glucose 6-phosphate de-
hydrogenase and 6-phosphogluconate dehydrogenase
activities were directly proportional to sample volumes
between 5 and 50 μΐ, but deviations from linearity were
found for larger sample volumes. On the other hand, the
measurement of the glucose 6-phosphate dehydroge-
nase/6-phosphogluconate dehydrogenase index was
found to be essentially independent of the sample vol-
ume.
Accuracy was assayed separately for glucose 6-phos-
phate dehydrogenase and 6-phosphogluconate dehydro-
genase activities. Figure 1 illustrates the results of the
comparison of the glucose 6-phosphate dehydrogenase
activities measured by the proposed method and by the
previously described method performed with the mo-
nostarter kit. Glucose 6-phosphate dehydrogenase activi-
ties were well correlated (left graph of fig. 1). The glu-
cose 6-phosphate dehydrogenase/6-phosphogluconate
dehydrogenase index was also well correlated with the
glucose 6-phosphate dehydrogenase activity, but the
standard error of the estimate (S^) indicated a slightly
higher dispersion of the sample data points around the
regression line. The 6-phosphogluconate dehydrogenase
activity measured by the proposed method was com-
pared with that measured, on the same samples, by the
ICSH reference method. These results, shown in figure
2, proved a good correlation between'the proposed and
the reference method.
The performance of the autosampler was tested by run-
ning five times a set of eight samples from glucose 6-
phosphate dehydrogenase non-deficient adult males and
three samples of heterozygotes for the G6PDMeditemmean
variant. From each sample 300 μΐ of whole blood were
directly loaded into the autosampler tubes, which were
then processed in series. Figure 3 shows the results of
this test. As can be seen, as a result of erythrocyte sedi-


















Fig. 2 Comparison between the differential pH and the ICSH
methods for 6-phosphogluconate dehydrogenase activity.
Regression line: y = 0.779x - 44; η = 23; r = 0.991; S^ = 45.
Ο 1000 2000 3000 4000
Glucose 6-phosphate dehydrogenase
(reference method) [U/l]
Fig. 1 Comparison between the presently described methods (y)
and the previously reported optimised glucose 6-phosphate dehy-
drogenase assay test (x) for glucose 6-phosphate dehydrogenase
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Syx = 75) and the glucose 6-phosphate dehydrogenase/6-phospho-
gluconate dehydrogenase index (right; regression line: y = 0.0006x
+ 0.11; n = 80; r = 0.948; Syx = 0.18).
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Fig. 3 Performance of the autosampler loaded with undiluted
whole blood samples. The same batches of normal males (full
circles; n = 8) and of heterozygous Q6PDMedUerranean females (open
triangles; n = 3) were analysed at different times after loading in
the autosampler. The reference intervals are depicted by the dashed
areas. Each point is the average of the batch.
drogenase and 6-phosphogluconate dehydrogenase
activities tend to increase after standing in the autosam-
pler for different times before the analysis. However, the
glucose 6-phosphate dehydrogenase/6-phosphogluco-
nate dehydrogenase index was found to be totally inde-
pendent from this phenomenon, with a concomitant sig-
nificant discrimination of the glucose 6-phosphate dehy-
drogenase-deficient samples from normals.
Table 2 reports the reference intervals partitioned by sex
and by the presence of a- or -thalassaemia. In the
males G6PDMediterranean-positive group, visual inspection
of the distributions and statistical analysis indicated that,
in the presence of -thalassaemia, the U/g Hb of both
enzymes and the glucose 6-phosphate dehydrogenase/6-
phosphogluconate dehydrogenase indexes were all
shifted to higher values (P < 0.001 for all the compari-
sons). In the G6PDMcditcrrancan-positive males with a-tha-
lassaemia the activities were still significantly higher
than in normals, although to a lesser extent. In the few
cases of subjects with iron deficiency (not shown) we
observed an intermediate pattern between the a- and -
thalassaemia carriers. 6-Phosphogluconate dehydroge-
nase activity was significantly different between normal
Q6pDMediterrancan.positive maleg an(j normal G6PDMedit'
erranean_positive femaleS9 wjth fa ]atter showing the
higher activities (P < 0.001).
The DNA analysis of glucose 6-phosphate dehydroge-
nase gene with particular attention to the presence of the
G6pDMediterranean variant js reported 1Π figure 4. The
PCR amplified region of the glucose 6-phosphate dehy-
drogenase gene encompassing exons VI and VII is a
fragment of 547 base pairs (fig. 4, lane 1). The frag-
ments obtained from a glucose 6-phosphate dehydroge-
nase normal subject after Mbo II digestion and visible
on the gel are of 377 base pairs and 119 base pairs (fig.
4, lane 2). The presence of the C —+ T mutation at posi-
tion 563 in exon VI of the glucose 6-phosphate dehydro-
genase gene creates a novel Mbo II site, so that heterozy-
gotes for G6PDMcditcrrancan show, in addition to the 377
base pairs and 119 base pairs fragments, two bands of
277 base pairs and of 100 base pairs, respectively (fig.
4, lane 3). Subjects homozygote for G6PDMeditcrranean
Tab. 2 Reference intervals. Data are expressed as means ± SD. Parametric centiles 2.5—97.5, calcu-
lated for n > 30, in italics. 6-Phosphogluconate dehydrogenase and glucose 6-phosphate dehydrogenase









Males, glucose 6-phosphate dehydrogenase non-deficient phenotype
Non-Thalassaemic 59 8.6 ± 1.0 6.6 ± 0.8
6.6-10.6 5.0- 8.2
-Thalassaemia 27 15.6 ± 2.1 9.4 ± 1.5
a-Thalassaemia 19 10.3 ± 1.4 7.2 ± 0.9
Males, glucose 6-phosphate dehydrogenase deficient phenotype
Non-Thalassaemic 7 0.7 ± 0.5 7.2 ± 0.5
-Thalassaemia 3 0.7 ± 0.2 8.9 ± 0.9
a-Thalassaemia 2 0.6 7.8
Females, glucose 6-phosphate dehydrogenase non-deficient phenotype
Non-Thalassaemic 30 8.3 ± 1.5 8.0 ± 1.0

















Fig. 4 Restriction enzyme analysis of amplified glucose 6-phos-
phate dehydrogenase gene.
Lane 1: undigested amplified fragment;
lane 2: normal control;
lane 3: heterozygous female for G6PDMcditcrranean;
lane 4: homozygous female for G6PDMcdilcrrancan;
lane 5: size markers (pBR 322 Msp I digested).
Numbers of base pairs relative to the main bands are on the left.
showed only fragments of 277 base pairs, 119 base pairs
and 100 base pairs (fig. 4, lane 4).
Finally, a comparison of the diagnostic sensitivities of
the properties glucose 6-phosphate dehydrogenase activ-
ity and glucose 6-phosphate dehydrogenase/6-phospho-
gluconate dehydrogenase index was performed with the
help of the data presented in figure 5. The glucose 6-
phosphate dehydrogenase activity in 25 G6PDMediterra"
ncan heterozygote women was 5.96 ± 1.62 U/g Hb (mean
± SD). In 4 subjects the glucose 6-phosphate dehydro-
genase activity was within the reference intervals estab-
lished on normal non-deficient adult males, while in
21/25 (84.0%) subjects the glucose 6-phosphate dehy-
drogenase activity was below such reference intervals.
However, the glucose 6-phosphate dehydrogenase/6-
phosphogluconate dehydrogenase index in the same sub-
jects was 0.64 ±0.19. In only one subject the index was
within the reference intervals established on normal non-
deficient adult males, while in 24/25 of the heterozygote
women (96.0%) the glucose 6-phosphate dehydroge-
nase/6-phosphogluconate dehydrogenase index was be-
low the reference intervals of the normal G6PDMcditcrra-
ncan-positive males.
Discussion
A new method for the rapid determination of glucose 6·̂
phosphate dehydrogenase activity in whole blood with
the differential pH technique is presented. This method
requires 25 μΐ of whole blood, is automated and seems
quite reliable. The assay conditions differ from those
previously reported (10) principally with regard to the
following points:
(a) the working pH is 8.0 instead of 9.2, and the buffer
has been changed (TRIS 10 mmol/1, KC1 100 mmoVl
and EDTA 0.5 mmol/1 instead of glycylglycine 7.0
mmol/1, glycine 6.5 mmol/1 and KC1 150 mmol/1);
(b) the 6-phosphogluconate dehydrogenase activity is
measured separately from that of glucose 6-phosphate
dehydrogenase so that the glucose 6-phosphate dehydro-
genase/6-phosphogluconate dehydrogenase index can
be calculated.
The new pH and buffer were essential, in order to obtain
a sufficiently strong signal from the 6-phosphogluconate
dehydrogenase activity, which at pH 9.2 is inhibited by
almost 80% (9). Therefore, we decided not to optimise
the old protocol but to present a new method that corre-
lates well with the ICSH standard assay (13). Under the
actual conditions, both glucose 6-phosphate dehydroge-
nase and 6-phosphogluconate dehydrogenase activities
can be measured with good reproducibility, although
maximal enzyme activity is not attained. In fact, the
agreement between our and ICSH method for both glu-
cose 6-phosphate dehydrogenase and 6-phosphogluco-
nate dehydrogenase is good. Moreover, the glucose 6-
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Fig. 5 Glucose 6-phosphate dehydrogenase (left) and glucose 6-
phosphate dehydrogenase/6-phosphogluconate dehydrogenase
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nase non-deficient males G6PDB, in 25 G6PDMcditemmean female
carriers (G6PDB/G6PDMcd) and in 9 glucose 6-phosphate dehydro-
genase1 deficient males (G6PDMed).
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non-deficient males established by the differential pH
method (8.6 ± 1.0 U/g Hb) is very close to that reported
by the ICSH committee for a group of only 10 subjects
(8.3 ± 1.6U/gHb;(13)).
With regard to the new double-starter procedure here
reported, preliminary experiments indicated that the 6-
phosphogluconate dehydrogenase activity is correctly
evaluated by the new double-starter procedure reported
here, irrespective of whether 6-phosphogluconate is the
first or second substrate added to the mixing chamber.
Particular attention should be paid to the stability of the
6-phosphogluconate solution. It cannot be stored at 4 °C
for more than five days, since 6-phosphogluconate is
then hydrolysed and its concentration becomes rate-lim-
iting. We also noticed significant differences in the 6-
phosphogluconate dehydrogenase activity measured
with 6-phosphogluconate purchased from Sigma or
Boehringer, and also between different batches of the
Boehringer reagent. It has already been reported that
contamination with impurities varies greatly from manu-
facturer to manufacturer and between lots (18). The use
of appropriate control materials, such as glycerol-stabi-
lised haemoiysates (14), allows for the detection of such
differences and for an eventual correction of the data.
The measurement of the glucose 6-phosphate dehydro-
genase/6-phosphogluconate dehydrogenase index by the
proposed method significantly improves the sensitivity
of detection of the heterozygotes for G6PDMcditcrranean.
This is probably due to the restricted distribution of the
enzymatic activities, both in normal and in heterozy-
gotes. Among our group of heterozygotes the glucose 6-
phosphate dehydrogenase/6-phosphogluconate dehydro-
genase indexes were homogenously distributed, without
any evidence of the extreme phenotypes previously
found by Rinaldi et al. (19), and with an incidence of
approximately 5.1% among the heterozygotes. More-
over, the distribution of glucose 6-phosphate dehydroge-
nase/6-phosphogluconate dehydrogenase red cell activi-
ties in our sample of 25 Sardinian heterozygotes for the
G6pDMediterranean mutant was essentially uniform, with-
out any skew toward the normal non-deficient subjects.
This finding could be of interest in view of the extensive
use of glucose 6-phosphate dehydrogenase and other X-
linked markers as probes of monoclonality in cell pop-
ulations.
The use of the autosampler loaded directly with undi-
luted blood specimen significantly reduces the labora-
tory work load and does not require any specialized
knowledge of the differential pH apparatus. In doubtful
cases, the described simple method of DNA analysis
permits the definition of the genotype relative to the oc-
currence of the G6PDMeditcrrancan mutant. Other classical
cytochemical methods can be performed to assess the
genotype in the presence of rarer glucose 6-phosphate
dehydrogenase variants (20, 21).
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